Chia Tai Tianqing's HER2 Bispecific ADC TQB2102 NDA Accepted for Review
nashnova research
Chia Tai Tianqing, a subsidiary of Sino Biopharmaceutical (01177), has had its new drug application for TQB2102 accepted by China's NMPA, targeting HER2-low breast cancer. It is the first bispecific ADC globally to post positive Phase III results in this setting — giving the company a first-mover edge in a closely watched race.
What does this drug treat, and how far along is it?
TQB2102's accepted indication covers unresectable or metastatic HER2-low adult breast cancer patients who have not received prior chemotherapy in the advanced setting.
HER2-low — where the HER2 protein is present on tumour cells at low levels, too low for traditional HER2-targeted drugs to work well — is a widely recognised unmet need in breast cancer treatment.
This means → if TQB2102 ultimately wins approval, it addresses a patient population poorly served by existing therapies, with a clear market opening.
What did the Phase III data show?
The pivotal study enrolled 543 patients. At interim analysis, it met both the pre-specified primary endpoint and key secondary endpoints.
Compared with investigator's-choice chemotherapy, TQB2102 significantly reduced the risk of disease progression or death. Progression-free survival — the time a patient's tumour does not worsen — showed both statistically and clinically meaningful improvement.
In plain terms = the benefit was not marginal. It was large enough to rule out chance statistically and to change treatment decisions clinically. Full data will be presented at an international medical conference.
What makes the drug's design different?
The antibody uses an asymmetric biparatopic design — it grips two distinct domains (ECD II and ECD IV) on the HER2 protein simultaneously, boosting binding and internalisation into tumour cells.
The linker is enzyme-cleavable, enabling a "bystander effect" — once the drug payload is released, it can also kill neighbouring cancer cells — which widens its reach against heterogeneous tumours.
The drug-antibody ratio (the number of toxic payloads loaded onto each antibody) is optimised to roughly 5.8–6.0, carrying a topoisomerase I inhibitor. This means → higher tumour-killing potency while keeping toxicity in check, overcoming the limitations of conventional single-target ADCs in HER2-low cancers.
Beyond breast cancer — what other indications are in the pipeline?
TQB2102 has multiple Phase III studies under way, spanning different HER2 expression levels and tumour types.
These include HER2-positive breast cancer (neoadjuvant, first-line, and later-line), as well as HER2-positive biliary tract cancer and colorectal cancer in later-line settings.
Three indications have already been granted Breakthrough Therapy Designation. This reflects a growing regulatory acknowledgment of TQB2102's broader clinical value.
How far along is commercialisation, and where is the money coming from?
In August 2026, Sino Biopharmaceutical signed an exclusive licence-and-supply deal with Cipla, granting Cipla development and commercialisation rights in India, South Africa, and five other emerging markets. Chia Tai Tianqing retains manufacturing and supply.
To date, TQB2102 has secured two regional licensing deals, generating a combined ~US$30 million in upfront and milestone payments.
In plain terms = the drug has not yet launched, but licensing revenue is already flowing back — validating its commercial appeal in overseas markets. The next key milestone is how smoothly the NDA review proceeds in China, the asset's core market.
市场有风险，内容仅供研究参考，不构成投资建议。